中药注射剂联合CF化疗方案治疗乳腺癌的贝叶斯网络Meta分析
该贝叶斯网络Meta分析纳入84项RCT共7855例乳腺癌患者,比较9种中药注射剂联合环磷酰胺与5-氟尿嘧啶(CF)化疗方案的疗效与安全性。结果显示,参芪扶正、复方苦参、艾迪和康艾注射剂联合CF化疗方案效果较显著,但结论仍需更多高质量、正确使用盲法和分配隐藏的RCT支持。
要点
- 参芪扶正、复方苦参、艾迪、康艾注射剂联合CF化疗方案对乳腺癌患者效果更显著
- 参芪扶正注射剂被认为是缓解不良反应的有利选择
- 艾迪和复方苦参注射剂联合CF在临床有效率和体能状态方面更有利
核心结论
- 参芪扶正、复方苦参、艾迪和康艾注射剂联合CF化疗方案对乳腺癌患者有更显著的效果。
- 仍需更多高质量、正确使用盲法和分配隐藏的RCT来支持结论。
研究设计与样本
- 贝叶斯网络Meta分析,检索多个电子数据库至2020年1月6日,纳入84项RCT共7855例患者,涉及9种中药注射剂。
- 采用Cochrane偏倚风险评估工具评价RCT质量,使用Winbugs 1.4.3和Stata 13.0软件分析。
- 应用累积排序曲线下面积(SUCRA)概率值对治疗进行排序,并进行聚类分析比较两种或三种结局的效果。
主要发现
- 与单纯CF化疗方案相比,艾迪、参麦、参芪扶正、康艾、康莱特或生脉注射剂联合CF可提高临床有效率。
- 艾迪、参麦、参芪扶正、复方苦参、康艾和康莱特注射剂联合CF可改善体能状态。
- 参芪扶正注射剂被认为是缓解不良反应的有利选择。
- 聚类分析结果显示,艾迪注射剂和复方苦参注射剂联合CF在临床有效率和体能状态方面更有利。
临床怎么用
- 对于乳腺癌患者,可考虑在CF化疗方案基础上联合参芪扶正、复方苦参、艾迪或康艾注射剂以改善疗效。
- 参芪扶正注射剂可能有助于缓解化疗不良反应。
- 艾迪和复方苦参注射剂联合CF可能同时改善临床有效率和体能状态。
局限性
- 需要更多高质量临床RCT,特别是正确使用盲法和分配隐藏的研究来支持结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Given the limitations of chemotherapy for the treatment of breast cancer (BC) and the wide exploration of Chinese herbal injections (CHIs), this network meta-analysis (NMA) was conducted to analyze the comparative efficacy and safety of nine CHIs combined with CF (Cyclophosphamide and 5-Fluorouracil) chemotherapy regimens in the treatment of BC. Methods: Several electronic databases were searched to identify randomized controlled trials (RCTs) from inception to January 6, 2020. RCTs were screened by pre-established eligibility criteria, and the quality of which was assessed using the Cochrane risk of bias tool. Outcomes such as the clinical effectiveness rate, performance status, peripheral hemogram, and detection of T-lymphocyte subsets were analyzed using the Winbugs 1.4.3 and Stata 13.0 software. Surface under the cumulative ranking curve (SUCRA) probability values were applied to rank the examined treatments. Cluster analysis was performed to compare the effect of CHIs between two or three different outcomes. Results: A total of 84 RCTs involving 7855 patients and nine CHIs were included. The results showed that compared to CF chemotherapy regimens alone, the ones injected along with Aidi, Shenmai, Shenqi Fuzheng, Kangai, Kanglaite, or Shengmai combined with CF can improve the clinical effectiveness rate. Aidi, Shenmai, Shenqi Fuzheng, Compound Kushen, Kangai, and Kanglaite injection combined with CF can improve the performance status. Shenqi Fuzheng injection was considered as a favorable choice for relieving adverse reactions. According to the results of cluster analysis, Aidi injection and Compound Kushen injection plus CF were more favorable for the clinical effectiveness rate and performance status. Conclusion: In conclusion, Shenqi Fuzheng, Compound Kushen, Aidi, and Kangai injection combined with CF chemotherapy regimen have more significant effects for patients with BC. However, more high-quality clinical RCTs, especialy which correctly use blinding and allocation concealment, are required to support the conclusions.
引用
- Liu S, Wang H, Wang M, et al. Comparative Efficacy and Safety of Chinese Herbal Injections Combined With Cyclophosphamide and 5-Fluorouracil Chemotherapies in Treatment of Breast Cancer: A Bayesian Network Meta-Analysis. Front Pharmacol. 2021. PMID: 33708106. doi:10.3389/fphar.2020.572396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。